Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
about
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaRole of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitroGenotypes Affecting the Pharmacokinetics of Anticancer Drugs.ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.OCT1 and imatinib transport in CML: is it clinically relevant?Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.Defining the target and the effect of imatinib on the filarial c-Abl homologue.Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia.Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC-MS/MS.Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro.RETRACTED ARTICLE: ABCB1 (1199G>A) polymorphism regulates the efficacy of docetaxel and imatinib mesylate in HEK293 recombinant cell lines.Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia.Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemiaThe significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
P2860
Q26781539-7C849C9D-8320-41B1-B9F2-31AB245E99ABQ34871636-662D7719-85BA-42C3-A0A1-7F4F3163FD35Q36229161-ABB04C91-E0F3-44C4-9855-29F23AAAE10DQ37140624-44EE99C1-AE74-4A8D-9237-650389CE8AEEQ37685527-AC63D1E4-8EDA-4F0B-B3E1-B336417C9E9DQ38253243-37DFDB03-7F0E-401B-8434-6427D5948B61Q38540022-05F7A9F4-B451-49AD-850B-6121B5E411C6Q38622785-14E47588-7251-414F-9EE8-65F68EAE1001Q38826494-1927F74F-0375-48B1-866A-57E0F729CCCEQ38848383-01CDB0F7-7984-468B-9EC0-6B289037A86DQ38996487-3541FA98-64FA-4717-AD10-177FB9C98866Q39031326-50CAFE6E-1004-45E9-B94B-3ED7FD10D3C6Q39116591-549A58B9-AAC2-446C-AC15-F1CBBA23F02EQ39231153-7439C619-2228-4C78-987C-6A90424616A4Q40126435-3284A26E-4703-4445-97E6-B9D2F86437C5Q41144255-8883561B-6A35-431B-A8B2-EF889C03613CQ41509859-142212D7-AC4B-4E00-9CA7-3431A6410279Q50261890-3D3FA0AC-84E7-40E4-8B49-3C9C25EB0E89Q51251518-3B5F9B56-2DD9-4B88-A9C9-FBBE3C262FD5Q53006929-D6F595E6-9AEC-4984-940D-8F4A68FEDFF6Q53733924-7322D8FF-A4F9-4E70-A27D-1DD79B9E153EQ53803475-12E709B8-B4DA-4888-B116-C0D411C44FF3Q55070104-4CD0F8D9-2019-42B1-BF71-2D0BD2DE146DQ56973578-2E4CEBA9-72E8-4113-AFFA-509CA3BB8782Q58588447-C05625BA-607D-4AD1-A85F-A5BD5E8335C4
P2860
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Influence of enzyme and transp ...... nic myeloid leukemia patients.
@en
type
label
Influence of enzyme and transp ...... nic myeloid leukemia patients.
@en
prefLabel
Influence of enzyme and transp ...... nic myeloid leukemia patients.
@en
P2093
P356
P1433
P1476
Influence of enzyme and transp ...... nic myeloid leukemia patients.
@en
P2093
P304
P356
10.1093/ANNONC/MDS532
P577
2012-10-31T00:00:00Z